Maysaa Basha, MD
Neurology · Detroit, MINPI 1073781571
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,860 of the $8,043 with a category attached, or 60.4%. Eisai Inc. accounts for 78.9% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $6,587 and has fallen 95.7% since, to $282 in 2025.
Across 71 payments — averaging $113.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$6K
- Novartis$446
- UCB, Inc.$346
- Neurelis, Inc.$238
- Neuropace, Inc.$169
- Nevro Corp.$143
- plus $351 from 8 others
Across 31 payments — averaging $2552.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$40K
- Sunovion Pharmaceuticals Inc.$36K
- Pfizer$3K
What the payments were for
- Consulting fees$4,86060%
- Travel & lodging$94512%
- Food & beverage$2,11926%
- Education$1191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 14 | $6,350 |
| Novartis | 25 | $446 |
| UCB, Inc. | 13 | $346 |
| Neurelis, Inc. | 5 | $238 |
| Neuropace, Inc. | 2 | $169 |
| Nevro Corp. | 1 | $143 |
| SK Life Science, Inc. | 3 | $120 |
| Livanova USA, Inc. | 2 | $112 |
| TG Therapeutics, Inc. | 1 | $25 |
| Smith+Nephew | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Aucta Pharmaceuticals, Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Zogenix Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fycompa$5,930
- RNS Neurostimulator Kit$154
- Senza Spinal Cord Stimulation System$143
- KESIMPTA$133
- Briviact$125
How this compares
$8,043 in reported general payments places this provider in the 75th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 63 | $86,347 |
| Oxtellar XrOxcarbazepine | 42 | $75,995 |
| OnfiClobazam | 22 | $63,801 |
| FycompaPerampanel | 48 | $56,527 |
| AptiomEslicarbazepine Acetate | 25 | $45,090 |
| XcopriCenobamate | 19 | $24,403 |
| NeurontinGabapentin | 12 | $17,828 |
| Lacosamide | 200 | $16,913 |
| Lamotrigine ErLamotrigine | 40 | $15,582 |
| Clobazam | 138 | $8,373 |
| LyricaPregabalin | 12 | $7,192 |
| DilantinPhenytoin Sodium Extended | 16 | $3,775 |
| Carbamazepine ErCarbamazepine | 28 | $3,487 |
| Levetiracetam | 104 | $2,905 |
| Oxcarbazepine | 43 | $2,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact | $346 | $86,34763 claims |
| Eisai Inc.Fycompa | $6,350 | $56,52748 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $19 | $45,09025 claims |
| SK Life Science, Inc.Xcopri | $120 | $24,40319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 652 neurology providers in Michigan.
Other neurology in Detroit
- Bisena BulicaDetroit$900K
- Evanthia BernitsasDetroit$255K
- Andrew RussmanDetroit$118K
- Alex CheblDetroit$68K
- Tobias WalbertDetroit$56K
- Panayiotis VarelasDetroit$48K
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Wade CooperAnn Arbor$991K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.